FADE IN:
LIFESPAN
"Aging is a disease, and that disease is treatable." — David Sinclair
Act One
THE INFORMATION THEORY OF AGING
INT. UNIVERSITY OF NEW SOUTH WALES — GENETICS LAB — DAY (1993)
Sydney, Australia. YOUNG DAVID SINCLAIR (24) stares into a microscope at yeast cells. His PhD advisor watches from across the lab. Sinclair has been here for eighteen hours. He hasn't eaten. His eyes are red.
SINCLAIR
(voiceover)
I was studying yeast. Yeast. The most boring organism on the planet. But in those cells, I found something that would change everything I believed about life, death, and the space between them. A gene called SIR2 — a master regulator. When I activated it, the yeast cells lived thirty percent longer. Not just longer. Healthier. It was as if I had slowed down time itself.
INT. MIT — LEONARD GUARENTE'S LAB — DAY (1995)
Sinclair has moved to MIT for his postdoctoral work under Lenny Guarente, one of the founding fathers of aging research. The lab is competitive, brilliant, relentless. Sinclair stands before a whiteboard, drawing molecular pathways.
SINCLAIR
SIR2 is a sirtuin — an enzyme that repairs DNA and maintains the epigenome. When cells are stressed, sirtuins get pulled away from their normal job to fix the damage. Over time, the epigenome degrades. Genes that should be on turn off. Genes that should be off turn on. That is aging. Not mutation. Information loss.
THE LAB PARTNER
(skeptical)
You're saying aging isn't about our DNA breaking down? It's about our cells losing the ability to read their own instructions?
SINCLAIR
Exactly. Think of DNA as a compact disc. The information is still there. But the surface gets scratched. The cell can't read the data anymore. Aging is not the destruction of information. It's the loss of the ability to access it. And if we can restore that access — polish the disc, as it were — we can reverse aging itself.
INT. HARVARD MEDICAL SCHOOL — SINCLAIR LAB — DAY (1999)
Sinclair, now 30, has his own lab at Harvard. It's small. Underfunded. His desk is covered with grant proposals, most of them rejected. He stares at a letter from a funding agency.
SINCLAIR
(reading, frustrated)
"While the proposed research on sirtuin activation is creative, the committee does not believe that aging can be meaningfully slowed in mammals. Funding denied."
SANDRA
(on the phone)
Another rejection?
SINCLAIR
They say aging can't be slowed. They're wrong. Every organism we've tested shows the same pattern: activate the sirtuins, repair the epigenome, extend lifespan. It works in yeast. It works in worms. It works in flies. And I will prove it works in mice. I just need someone to believe me long enough to fund the research.
INT. SINCLAIR LAB — HARVARD — NIGHT (2003)
Sinclair and THE LAB PARTNER stare at data on a screen. Mouse lifespan curves. The treated mice — given a sirtuin activator called resveratrol, found in red wine — are living significantly longer than the control group. And they're not just living longer. They're healthier.
THE LAB PARTNER
(whispering)
David. Look at this. The treated mice on a high-fat diet are living as long as the mice on a normal diet. They're not getting fat. They're not getting diabetes. They're running on the treadmill like young mice. At the equivalent of seventy human years.
SINCLAIR
(sitting down slowly)
We just showed that aging in mammals can be slowed by a molecule. A single molecule. Found in grape skins. This changes everything.
In 2003, Sinclair's lab published a landmark paper in Nature showing that resveratrol activates sirtuins and extends lifespan in model organisms. The paper became one of the most cited in the history of aging research.
INT. CONFERENCE ROOM — NIH — WASHINGTON, D.C. — DAY (2004)
Sinclair presents to THE NIH DIRECTOR and a panel of senior scientists. His slides show the resveratrol data. The room is skeptical.
THE NIH DIRECTOR
Dr. Sinclair, you are proposing that aging is a disease. Not a process. Not an inevitability. A disease. Do you understand how radical that claim is?
SINCLAIR
I understand how radical the data is. Every chronic disease — cancer, heart disease, Alzheimer's, diabetes — has aging as its primary risk factor. We spend billions treating each disease individually. But if aging itself is the underlying cause, and if we can slow or reverse it, we don't just add years to life. We subtract decades of disease. The math is irrefutable.
THE NIH DIRECTOR
(long pause)
And if you're wrong?
SINCLAIR
Then I will have spent my career investigating the most important question in biology and been wrong. I can live with that. What I can't live with is knowing the answer might be within reach and choosing not to look.
Act Two
THE EPIGENETIC REVOLUTION
INT. SINCLAIR LAB — HARVARD — DAY (2012)
The lab has grown. Thirty researchers. Millions in funding. Sinclair's focus has shifted from resveratrol to NMN — nicotinamide mononucleotide — a molecule that boosts NAD+, a critical coenzyme that declines with age.
SINCLAIR
(to the lab team)
NAD+ levels drop fifty percent between age twenty and fifty. It's one of the most dramatic biochemical changes in the human body. And when NAD+ drops, the sirtuins can't function. Without sirtuins, the epigenome degrades. Without the epigenome, cells lose their identity. A liver cell starts acting like a skin cell. That's aging. And NMN restores NAD+ levels. In our mice, it's like turning back the clock.
THE LAB PARTNER
The old mice on NMN — their blood vessels look young. Their muscles look young. Their cognitive function looks young. It's not just lifespan. It's healthspan. Everything we wanted from resveratrol, NMN delivers at a higher level.
INT. SINCLAIR'S OFFICE — HARVARD — DAY (2016)
Sinclair sits across from THE AUSTRALIAN FATHER — his own father, Andrew, now 79, via video call from Sydney.
THE AUSTRALIAN FATHER
David, I'm seventy-nine. I feel seventy-nine. My doctor says everything is "normal for my age." I hate that phrase. Normal for my age means declining. Deteriorating. Dying slowly. I don't want normal. I want what you're giving those mice.
SINCLAIR
(careful)
Dad, the human trials are still years away. I can't guarantee —
THE AUSTRALIAN FATHER
I'm not asking for guarantees. I'm asking for a chance. You've been studying this for twenty years. You take NMN yourself. You take metformin. You take resveratrol. Are you going to tell your own father he can't try?
SINCLAIR
(long pause, then smiling)
I'll send you the protocol.
Andrew Sinclair began taking NMN and metformin at 79. By his own account and his son's observations, he reported improved energy, cognitive function, and physical capability. He began whitewater rafting and traveling extensively in his eighties.
INT. SINCLAIR LAB — HARVARD — NIGHT (2020)
A breakthrough. THE LAB PARTNER rushes to Sinclair's office with data. Old mice treated with Yamanaka factors — the same genes used to create stem cells — have had their vision restored. Blind mice can see again. Their eye cells have been reprogrammed to a younger state.
THE LAB PARTNER
(breathless)
David. The old mice. The ones with crushed optic nerves. We expressed three of the four Yamanaka factors. Their retinal ganglion cells regenerated. They can see. Old, blind mice can see.
SINCLAIR
(standing up slowly)
We just reversed aging in a living tissue. Not slowed it. Reversed it. The cells remembered what they were supposed to be. The information was still there. We just helped them read it again.
THE LAB PARTNER
This is the proof. Aging is information loss. And information can be restored.
In December 2020, Sinclair's lab published a landmark paper in Nature showing that epigenetic reprogramming could restore vision in old mice — the first demonstration of age reversal in a complex tissue in a living animal.
INT. BOOK LAUNCH EVENT — NEW YORK — DAY (2019)
The launch of "Lifespan: Why We Age — and Why We Don't Have To." A packed bookstore. Sinclair signs copies. The line stretches out the door.
READER IN LINE
Dr. Sinclair, I'm sixty-two. My doctor told me to accept that this is what getting old looks like. Your book says I don't have to. Is that true?
SINCLAIR
What I'm saying is that the science no longer supports the idea that aging is inevitable and untreatable. We have molecules that boost NAD+. We have metformin. We have caloric restriction mimetics. We have epigenetic reprogramming in the lab. The future of medicine is not treating the diseases of aging one by one. It's treating aging itself. And that future is closer than most people realize.
Act Three
THE RACE AGAINST TIME
INT. BIOTECH COMPANY — BOARD MEETING — DAY (2022)
Sinclair sits at the head of a table. His biotech company, Life Biosciences, has spun off multiple subsidiaries attacking different aspects of aging. Investors, scientists, and business executives surround him.
SINCLAIR
We are not building one company. We are building a platform. One subsidiary focuses on reprogramming. Another on NAD+ restoration. Another on senolytic therapies — clearing out zombie cells. Each one attacks a different mechanism of aging. Together, they represent the most comprehensive assault on aging ever attempted.
INVESTOR
Critics say you're overpromising. That the mouse results won't translate to humans. That you're selling hope.
SINCLAIR
I am selling hope. Backed by data. Published in Nature. Replicated by independent labs. The critics said the same thing about antibiotics, about vaccines, about gene therapy. The history of medicine is the history of skeptics being proven wrong by scientists who refused to stop.
INT. SINCLAIR'S HOME — BOSTON — EVENING (2023)
Sinclair takes his nightly supplements: NMN, resveratrol, metformin, vitamin D, vitamin K2. His children watch.
SINCLAIR'S DAUGHTER
Dad, are you going to live forever?
SINCLAIR
(laughing)
No one is going to live forever. But I think your generation will have the choice of how long to live. Not dictated by biology. By choice. That is the revolution. Not immortality. Agency. The ability to decide how long your body stays healthy and functional.
SANDRA
(from the kitchen)
Just make sure you live long enough to walk her down the aisle. That's the only protocol I care about.
INT. HARVARD — LECTURE HALL — DAY (2024)
Sinclair lectures to a packed hall of medical students. His slides show the before-and-after of epigenetic reprogramming in mice. The students are riveted.
SINCLAIR
You are the last generation of doctors who will treat aging as normal. The generation after you will treat it as a disease — because that is what the evidence says it is. Every chronic disease you will encounter in your careers has aging as its root cause. Solve aging, and you solve them all. That is Medicine 3.0. That is the future of your profession. And it starts now.
INT. SINCLAIR LAB — HARVARD — LATE NIGHT (2024)
Sinclair alone in his lab. Microscope. Data. The same posture he has held since he was a PhD student in Sydney, staring at yeast cells. Thirty years later, the organism is different — human cells now — but the question is the same.
SINCLAIR
(voiceover)
My grandmother died of Alzheimer's. My mother died of lung cancer. I watched the people I loved most in the world deteriorate, lose themselves, and vanish. And I decided that was unacceptable. Not inevitable. Unacceptable. Aging takes everything: your strength, your mind, your independence, your dignity. And for the first time in human history, we have the tools to fight back. Not someday. Now. The question is no longer whether we can slow aging. The question is whether we will choose to.
FADE OUT.
David Sinclair is a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. He has published over 200 scientific papers, holds more than 50 patents, and co-founded more than a dozen biotech companies. "Lifespan" has been translated into more than 40 languages. His father Andrew, who began taking NMN at 79, remains active in his late eighties. Sinclair continues his research into epigenetic reprogramming, believing that the first person to live to 150 may already be alive today.